Form 4 · Filed May 7, 2026, 12:38 AM UTC
GYRE/GYRE THERAPEUTICS, INC.
Eastling Thomas Wilson — Chief Financial Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
7 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 4, 2026 | A | other | 95,060 | $0 | — | 95,060 |
| May 4, 2026 | A | other | 47,530 | $0 | — | 47,530 |
| May 4, 2026 | A | other | 11,882 | $0 | — | 11,882 |
| May 4, 2026 | A | other | 33,271 | $0 | — | 33,271 |
| May 4, 2026 | A | other | 95,060 | $0 | — | 95,060 |
| May 4, 2026 | A | other | 92,683 | $0 | — | 92,683 |
| May 4, 2026 | A | other | 33,271 | $0 | — | 33,271 |
Source: SEC EDGAR raw filing ↗ · Accession 0001140361-26-019376